tbuckley/cabot-search huggingface dataset:
Edn1 Expression as a Novel Biomarker for Predicting Sorafenib Responsiveness in Patients with Hepatocellular Carcinoma
Authors: S.J. Yu, J.-K. Won, J.-H. Yoon, K.-H. Cho, W.-M. Choi, H. Cho, E.-J. Cho, J.-H. Lee, Y.J. Kim, K.-S. Suh, J.-J. Jang, C.Y. Kim
Journal: Journal of Hepatology (2016)
Aldosterone Enhances Cardiac Rupture After Myocardial Infarction Through Calcium/Calmodulin-Dependent Protein Kinase II
Authors: B. Julie He, Mei-Ling Joiner, Madhu Singh, Paari Dominic Swaminathan, Elizabeth Luczak, Olha Koval, William Kutschke, Chantal Allamargot, Jinying Yang, Xiaoqun Guan, Kathy Zimmerman, Isabella Grumbach, Robert Weiss, Douglas Spitz, Curt Sigmund, Matthijs Blankesteijn, Stephane Heymans, Peter Mohler, Mark Anderson
Journal: Circulation (2011)
Allogeneic Stem Cell Transplantation (ASCT) and Donor Lymphocyte Infusions (DLI) in the Management of Chronic Myelomonocytic Leukemia (CMML).
Authors: Michelle A. Elliott, Ayalew Tefferi, William J. Hogan, Louis Letendre, Dennis A. Gastineau, Stephan M. Ansell, Angela Dispenzieri, Morie A. Gertz, David J. Inwards, Martha Q. Lacy, Invana N. Micallef, Luis F. Porrata, Mark R. Litzow
Journal: Blood (2005)
Inflammation-Induced Adhesin-Receptor Interaction Provides a Fitness Advantage to Uropathogenic E. coli during Chronic Infection
Authors: Matt S. Conover, Ségolène Ruer, Joemar Taganna, Vasilios Kalas, Henri De Greve, Jerome S. Pinkner, Karen W. Dodson, Han Remaut, Scott J. Hultgren
Journal: Cell Host & Microbe (2016)
Lower Ferritin Concentrations in Children with Sickle Cell Disease Are Associated with Decreased Hemolysis and Lower Tricuspid Regurgitant Velocity
Authors: Oswaldo Castro, Caterina Minniti, Xiaomei Niu, Mehdi Nouraie, Craig Sable, Niti Dham, Sohail R Rana, Andrew Campbell, Gregory Ensing, Gregory J. Kato, Mark T. Gladwin, Victor R. Gordeuk
Journal: Blood (2008)
Relationship between Pattern of Hepatic Iron Deposition, Disease Severity and Clinical Outcomes in Non-Alcoholic Fatty Liver Disease
Authors: E. Buzzetti, R. Manguerra, A. Hall, L. De Luca, P. Manousou, P. Dhillon, M. Pinzani, A. Pietrangelo, E. Tsochatzis
Journal: Journal of Hepatology (2016)
Efficacy and Safety of Percutaneous Laser Ablation Therapy for Treatment of Large Hepatocellular Carcinoma
Authors: S. Camera, G.G. Di Costanzo, R. Tortora, L. Addario, F. Lampasi, Maria T. Tartaglione, V. Cossiga, L. Donnarumma, N. Caporaso, F. Morisco
Journal: Journal of Hepatology (2016)
Validation of 2 Explant-Based Recurrence Prognostic Models after Liver Transplantation for Hepatocellular Carcinoma in an External Cohort
Authors: C. Costentin, A. Notarpaolo, K. Boudjema, G. Magini, P. Bachellier, L. Meglioresi, F. Muscari, M. Gambato, E. Salame, F. Manenti, P.H. Bernard, C. D’Ambrosio, G.M. Ettore, C. Francoz, A. Vitale, S. Dharancy, P. Burra, C. Vanlemmens, S. Fagiuoli, A. Laurent, S. Radenne, J. Dumortier, M.N. Hilleret, T. Decaens, J. Calderaro, G. Amaddeo, F. Roudot-Thoraval, C. Duvoux
Journal: Journal of Hepatology (2016)
Establishment of Human Adipose Tissue-Derived Stromal Cell Lines: A Culture System to Manufacture Megakaryocytes Releasing Functional Platelets
Authors: Keiichi Tozawa, Yukako Ono-Uruga, Noriko Takizawa, Tadashi Horiuchi, Shin-ichiro Okamoto, Mitsuru Murata, Yasuo Ikeda, Yumiko Matsubara
Journal: Blood (2015)
P0355 : The evaluation of an automated recall programme for surveillance liver ultrasound in patients at increased risk of hepatocellular carcinoma
Authors: C. Farrell, T.J. Cross, A. Halpen, P.D. Richardson, P. Healey, J. Barr, N. Ladep, O. Noorullah, R.P. Sturgess, L. Boland, N. Stern, D. Palmer, M.G. Lombard, E. Joekes
Journal: Journal of Hepatology (2015)
The B3A2 junction type of the BCR-ABL oncogene is a favorable prognostic factor for a complete response to interferon treatment in patients with chronic myeloid leukemia (CML)
Authors: Efm Posthuma, R de Paus, H Kluin-Nelemans, B Beverloo, E Mensink, Jpp Meijerink, B Smit, Anne Hagemeijer-Hausman, R Wiliemze, Jhf Falkenburg
Journal: Blood (1998)
Hypermutation in Mantle Cell Lymphoma Does Not Indicate a Clinical or Biological Sub Entity.
Authors: Margit Schraders, Sabine Oeshker, Philip M. Kluin, Konnie Hebeda, Ed Schuuring, Martin-Leo Hansmann, Patricia J.T.A. Groenen, Joannes H.J.M. Van Krieken
Journal: Blood (2006)
Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort)
Authors: C. Costentin, R. Layese, V. Bourcier, L. Corvi, V. Petro-Sanchez, P. Marcellin, D. Guyader, S. Pol, D. Larrey, V. de Ledinghen, D. Ouzan, F. Zoulim, J.P. zarski, D. Roulot, A. Tran, J.-P. Bronowicki, G. Riachi, P. Cales, J.M. Péron, L. Alric, M. Bourlière, P. Mathurin, A. Sutton, E. Letouze, J. Zucman-Rossi, F. Roudot-Thoraval, P. Nahon
Journal: Journal of Hepatology (2016)
Demographics, Baseline Characteristics, and Disease Symptom Burden in RESPONSE-2: A Randomized, Phase 3 Study of Ruxolitinib in Polycythemia Vera Patients (pts) Who Are Resistant to or Intolerant of Hydroxyurea (HU)
Authors: Francesco Passamonti, Martin Griesshammer, Michele Cavo, Miklos Egyed, Giulia Benevolo, Timothy Devos, Jeannie Callum, Alessandro M. Vannucchi, Serdar Sivgin, Caroline Bensasson, Mahmudul Khan, Nadjat Mounedji, Guray Saydam
Journal: Blood (2015)
Internet-delivered cognitive behavior therapy for children and adolescents: A systematic review and meta-analysis
Authors: Sarah Vigerland, Fabian Lenhard, Marianne Bonnert, Maria Lalouni, Erik Hedman, Johan Ahlen, Ola Olén, Eva Serlachius, Brjánn Ljótsson
Journal: Clinical Psychology Review (2016)

Internet-delivered cognitive behavior therapy (ICBT) is a relatively novel treatment format with the potential to increase accessibility of evidence-based care. However, little is known about the feasibility and efficacy of ICBT in children and adolescents. We conducted a comprehensive systematic review and meta-analysis of ICBT for children and adolescents to provide an overview of the field and assess the efficacy of these interventions. A systematic literature search of six electronic databases was performed to identify ICBT intervention studies for children with a psychiatric condition, such as social anxiety disorder, or a somatic condition, such as chronic pain. Two reviewers independently rated study quality. Twenty-five studies, targeting 11 different disorders, were included in the review. Study quality and presentation of treatment variables, such as therapist time and treatment adherence, varied largely. Twenty-four studies (N = 1882) were included in the meta-analysis and ICBT yielded moderate between-group effect sizes when compared with waitlist, g = 0.62, 95% CI [0.41, 0.84]. The results suggest that CBT for psychiatric and somatic conditions in children and adolescents can be successfully adapted to an internet-delivered format.
Activation of Simultaneous Apoptosis and Necroptosis to Eradicate Drug Resistant Leukemia
Authors: Scott McComb, Julia Aguadé-Gorgorió, Blerim Marovca, Lena Harder, Gunnar Cario, Cornelia Eckert, Martin Schrappe, Martin Stanulla, Arend von Stackelberg, Jean-Pierre Bourquin, Beat Bornhauser
Journal: Blood (2015)
Why a developmental perspective is critical for understanding human cognition
Authors: Dean D'Souza, Annette Karmiloff-Smith
Journal: Behavioral and Brain Sciences (2016)

The evidence that Anderson (2014) marshals in support of his theory of neural reuse is persuasive. However, his theoretical framework currently lacks a developmental dimension. We argue that an account of the fundamental aspects of developmental change, as well as the temporal context within which change occurs, would greatly enhance Anderson's theory.
Phase II trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF-directed therapies.
Authors: E. M. Bertino, G. A. Otterson, M. A. Villalona-Calero, S. P. Nana-Sinkam, A. M. Ghany, K. R. Donthireddy, N. F. Abdel Karim, S. Cantrell, G. S. Phillips
Journal: Journal of Clinical Oncology (2010)

TPS291 Background: Non-small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancers diagnosed. In metastatic NSCLC, a platinum-based doublet remains the standard of care, with the addition of bevacizumab, an antiangiogenic agent, when feasible. Antiangiogenic agents result in improved response rates and survival, but bleeding is a significant potential toxicity. In particular, patients with squamous histology and a history of hemopytsis are excluded from treatment with this agent due to bleeding risk. Nab-paclitaxel, an albumin-bound formulation of paclitaxel, an agent commonly used in NSCLC treatment, was safe and effective in phase I/II studies, producing 16-30% response rates (RR). In a phase II study, combination treatment with nab-paclitaxel and carboplatin demonstrated improved efficacy (47% RR). The objective of this trial is to determine the response rate of nab-paclitaxel with carboplatin in patients who are ineligible for bevacizumab therapy. Methods: Eligible patients include adults with advanced NSCLC who are ineligible for bevacizumab therapy. These include patients with squamous histology, thrombotic or embolic events within 6 months, history of hemoptysis (controlled, non-life-threatening), cavitary lung lesions, and controlled brain metastases. Appropriate organ function (renal, hepatic and bone marrow) is also required, and significant pre-existing neuropathy is an additional exclusion criterion. Treatment consists of nab-paclitaxel 300 mg/m2 and carboplatin AUC 6 on day 1 of a 21-day cycle for up to six cycles. The trial is designed as a single arm, nonrandomized, two-stage Simon model; the first stage has enrolled 27 patients and the second stage will enroll 36 additional patients. The primary endpoint is response rate by RECIST criteria. Secondary objectives include progression-free and overall survival. Correlative studies include peripheral blood microRNA analysis as a pilot study to evaluate for predictive noninvasive biomarkers of response. No significant financial relationships to disclose.
The Dual Ccr2/Ccr5 Antagonist Cenicriviroc Ameliorates Steatohepatitis and Fibrosis in Vivo by Inhibiting the Infiltration of Inflammatory Monocytes into Injured Liver
Authors: T. Puengel, O. Krenkel, J. Mossanen, T. Longerich, E. Lefebvre, C. Trautwein, F. Tacke
Journal: Journal of Hepatology (2016)
Increased Bcl-xL as a compensatory response to antitumor agent ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid in thyroid cancer.
Authors: G. G. Chen, A. C. Vlantis, B. C. Leung, C. A. van Hasselt
Journal: Journal of Clinical Oncology (2010)

e16026 Background: Ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid (5F) is a chemical compound which is isolated from pteris semipinnata L (PsL). Studies have shown that 5F can inhibit the growth of head and neck tumors, including thyroid cancer, but the killing effect is moderate. Methods: Follicular thyroid cancer (FTC) cells were treated with 5F and the cell death was measured by MTT and TUNEL assays. Apoptotic molecules were determined by RT-PCR and Western blot. siRNA was used to regulate the key molecule. Results: We confirmed that 5F induced the moderate apoptosis in FTC cells, evident by MTT and TUNEL assays. In line with the increased apoptosis, 5F treatment led to the upregulation of pro-apoptotic tBid but no change in anti-apoptotic Bcl-2. Surprisingly, 5F also up-regulated the level of anti-apoptotic Bcl-xL in FTC cells. This is unexpected result since Bcl-xL overexpression is known to protect thyroid cancer cells from apoptosis. After treating FTC cells with Bcl-xL siRNA, it was found that 5F dramatically increased the apoptosis of FTC cells, compared with cells without Bcl-xL siRNA treatment. Accordingly, we believe that the up-regulation of Bcl-xL by 5F should be regarded as a compensatory response or self-defensive mechanism of thyroid cancer cells to protect them from death. Conclusions: The inhibition of Bcl-xL disarms its protective function, which is critically for treatment of FTC cells with 5F, as it can significantly enhance the killing efficiency of 5F. (This work was supported by a direct grant from the Chinese University of Hong Kong, Project No. 2008.1.065). No significant financial relationships to disclose.
Differentiation of Human Embryonic Stem Cells and Induced Pluripotent Stem Cells to Cardiomyocytes
Authors: Christine L. Mummery, Jianhua Zhang, Elizabeth S. Ng, David A. Elliott, Andrew G. Elefanty, Timothy J. Kamp
Journal: Circulation Research (2012)

Since human embryonic stem cells were first differentiated to beating cardiomyocytes a decade ago, interest in their potential applications has increased exponentially. This has been further enhanced over recent years by the discovery of methods to induce pluripotency in somatic cells, including those derived from patients with hereditary cardiac diseases. Human pluripotent stem cells have been among the most challenging cell types to grow stably in culture, but advances in reagent development now mean that most laboratories can expand both embryonic and induced pluripotent stem cells robustly using commercially available products. However, differentiation protocols have lagged behind and in many cases only produce the cell types required with low efficiency. Cardiomyocyte differentiation techniques were also initially inefficient and not readily transferable across cell lines, but there are now a number of more robust protocols available. Here, we review the basic biology underlying the differentiation of pluripotent cells to cardiac lineages and describe current state-of-the-art protocols, as well as ongoing refinements. This should provide a useful entry for laboratories new to this area to start their research. Ultimately, efficient and reliable differentiation methodologies are essential to generate desired cardiac lineages to realize the full promise of human pluripotent stem cells for biomedical research, drug development, and clinical applications.
Progression-Free Survival at 24 Months (PFS24) and Complete Response at 30 Months (CR30) from Autologous Stem Cell Transplantation (ASCT) Should be Used As Surrogates for OS in Follicular Lymphoma (FL) Patients
Authors: Ana Jiménez Ubieto, Carlos Grande García, Lucrecia Yañez, Dolores Caballero, Silvana Novelli, María Jesús Rodriguez, Marina Manzanares, Reyes Arranz, José Javier Ferreiro, Sabela Bobillo, Santiago Mercadal, Andrea Galego, Javier López Jiménez, Carlos Vallejo, Carmen Albo, Elena Pérez, Carmen Marrero, Laura Magnano, Luis Palomera, Isidro Jarque, Erika Coria, Teresa Palomo, Pilar Martinez Sánchez, Armando López-Guillermo, Antonio Salar, Juan José Lahuerta
Journal: Blood (2015)
Hepatic Encephalopathy in Patients with Non-Cirrhotic Portal Hypertension: Grade, Prevalence and Risk Factors
Authors: V. Nicoletti, S. Gioia, P. Lucatelli, S. Nardelli, C. Pasquale, I. Pentassuglio, S.N. Sobrinho, F. Greco, M. Merli, O. Riggio
Journal: Journal of Hepatology (2016)
Kinetics of Pulmonary Angiogenesis in Mouse Common Bile Duct Ligation-Induced Liver Fibrosis
Authors: S. Raevens, L. Devisscher, A. Paridaens, E. Bogaerts, S. Lefere, Y.-P. Vandewynckel, C. Casteleyn, K. Bracke, T. Maes, X. Verhelst, H. Van Vlierberghe, C. Van Steenkiste, A. Geerts, I. Colle
Journal: Journal of Hepatology (2016)
Retreatment of HCV DAA Failures: HCV Infection may be Incurable
Authors: C. Hezode, S. Fourati, G. Scoazec, A. Soulier, A. Varaut, M. Francois, I. Ruiz, A. Mallat, S. Chevaliez, J.-M. Pawlotsky
Journal: Journal of Hepatology (2016)
Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC
Authors: Daniel Morgensztern, Lingling Du, Saiama N. Waqar, Aalok Patel, Pamela Samson, Siddhartha Devarakonda, Feng Gao, Cliff G. Robinson, Jeffrey Bradley, Maria Baggstrom, Ashiq Masood, Ramaswamy Govindan, Varun Puri
Journal: Journal of Thoracic Oncology (2016)
Carcinosarcoma (CS) of the ovary: A single institution experience.
Authors: Margaux Jenna Kanis, Valentin Gueorguiev Kolev, Joelle Gertrajdman, Konstantin Zakashansky, Linus T. Chuang, Jamal Rahaman
Journal: Journal of Clinical Oncology (2014)

e16513 Background: We evaluated 25 patients with advanced stage CS of the ovary treated with surgical debulking followed by adjuvant chemotherapy and/or radiation at our institution. Methods: We performed a retrospective analysis of all patients treated for CS of the ovary between 1994 and 2011. The medical records were extracted for demographics, surgical staging, cytoreduction status and chemotherapy regimens. Results: A total of 33 patients with ovarian CS were identified. Of these, 28 were available for analysis. One patient was stage I (3.5%), two were stage II (11.1%), 20 were stage III (71.4%), and five (17.9%) were stage IV. The early stage patients were excluded from analysis. Of the 25 patients, 21 (84.0%) were optimally cytoreduced to a residual disease of <1cm and four (16.0%) were suboptimally cytoreduced. The median progression free survival (PFS) and overall survival (OS) was 10 and 21 months, respectively, for advanced stages. Twenty-one (75%) patients received adjuvant chemotherapy and 52.4% (11 of 21) of treated patients received paclitaxel/carboplatin (T/C) as first-line chemotherapy. The median PFS and OS was 14 and 21 months, respectively, for those treated with T/C. There was no difference in PFS (p=0.42) and OS (p=0.91) between the patients who received T/C vs. other chemotherapy regimens as a first-line adjuvant chemotherapy. Patients with optimal cytoreduction had an improved PFS compared to those with suboptimal cytoreduction (10 months vs. 4 months p= 0.019); however, there was no difference in OS (21 vs. 13 p=0.113). The two-year overall survival was 48.0%. Conclusions: Most patients with ovarian CS present with advanced stage disease. Treatment consists of optimal cytoreductive surgery followed by adjuvant chemotherapy. In our study, PFS was improved in patients who were optimally cytoreduced at the time of diagnosis. We demonstrate that T/C is an active regimen in the treatment of ovarian CS and has the potential to be the backbone for addition of biologic targeted therapies in the future. Use of first-line C/T in ovarian CS. Author Year No. of patients PFS/OS (months) Sit 2000 3 NR/19 Duska 2002 26 NR/27.1 Silasi 2008 4 6/38 Rauh-Hain 2011 50 11/24 Loizzi 2011 5 11/17 Chun 2011 18 35/53 Dai 2011 4 3.8/NR Current 2014 11 14/21
Noninferiority of S-1 to UFT/LV as adjuvant chemotherapy for stage III colon cancer: A randomized phase III trial (ACTS-CC).
Authors: Yoshihiko Nakamoto, Megumi Ishiguro, Motoki Yoshida, Koji Ikejiri, Izumi Mochizuki, Hidetaka Mochizuki, Kenjiro Kotake, Shingo Kameoka, Keiichi Takahashi, Toshiaki Watanabe, Masahiko Watanabe, Narikazu Boku, Naohiro Tomita, Yoshihiro Matsubara, Kenichi Sugihara
Journal: Journal of Clinical Oncology (2013)

3518 Background: The ACTS-CC trial is a phase III trial designed to validate non-inferiority of S-1 to UFT/LV, a standard treatment in Japan as adjuvant chemotherapy for stage III colon cancer. This is the first report which evaluated the efficacy of S-1 as adjuvant therapy for colon cancer. Methods: 20-80 aged patients with stage III colon cancer who underwent curative surgery were randomly assigned to receive S-1 (80, 100, or 120 mg/day according to BSA on days 1 to 28, followed by 14 days rest, 4 courses) or UFT/LV (UFT: 300 to 600 mg/day according to BSA and, LV: 75 mg/day on days 1 to 28, followed by 7 days rest, 5 courses). Primary endpoint was DFS. Sample size was 1,480 determined with one-sided alpha of 0.05, power of 0.80, and non-inferiority margin of hazard ratio (HR) of 1.29. Results: Among 1535 enrolled patients between Apr. 2009 and Jun. 2010, 1518 patients (758 in S-1 group, 760 in UFT/LV group) were included in the efficacy analysis. Median follow-up was 41.3 months, the mean age at enrollment was 64.5 years, wide lymph node dissection (D3) was done in 79.8%, the median number of dissected lymph nodes was 17, and stage IIIA/IIIB/IIIC were 15%/71%/14%. The 3-year DFS rate was 75.5% in S-1 group and 72.5% in UFT/LV group. The HR of DFS was 0.85 (95%CI: 0.70-1.03) and non-inferiority of S-1 was demonstrated (p&lt;0.0001). The completion rate of the protocol treatment was 76.5% in S-1 group and 72.5% in UFT/LV group. The overall incidence of grade ≥3 adverse events (AEs) in S-1 group and UFT/LV group were 16.0% and 14.4%: 4.4% and 5.5% for diarrhea, 4.9% and 3.5% for anorexia, 0.7% and 0.4% for leucopenia, 0.9% and 0.1% for anemia, 0.1% and 0.4% for thrombocytopenia, 1.2% and 1.5% for hyperbilirubinemia, 0.8% and 2.1% for AST elevation, and 1.1% and 3.3% for ALT elevation, respectively. Conclusions: Adjuvant therapy of S-1 for stage III colon cancer was demonstrated to be non-inferior in DFS to that of UFT/LV. Although AE profiles differed between S-1 group and UFT/LV group in this trial, incidence and degree of AEs were acceptable, and the completion rate of the protocol treatment was high. Adjuvant chemotherapy using S-1 will be a treatment option for stage III colon cancer. Clinical trial information: NCT00660894.
AL-335, a Once-Daily Pangenotypic Nucleotide HCV Polymerase Inhibitor, Demonstrates Potent Antiviral Activity over 7 Days in Treatment-Naïve Genotype 1-4 Patients
Authors: E. Berliba, T. Tsertsvadze, N. Ghicavii, D. Guyader, T. Kakabadze, C. Westland, S. Chanda, A. Patat, Q. Zhang, D. Smith, J. Yogaratnam, M. McClure, L. Beigelman, L. Blatt, J. Fry
Journal: Journal of Hepatology (2016)
44P Prognostic Value of Detection Method by Breast Cancer (BC) by Phenotype
Authors: O. Brouckaert, A. Schoneveld, C. Truyers, E. Kellen, I. Vergote, C. Van Ongeval, A. Van Steen, E. Van Limbergen, M. Christiaens, P. Neven
Journal: Annals of Oncology (2012)
MIR-873 Promotes Liver De-Differentiation and Fibrosis Targeting Glycine-N-Methyl Transferase
Authors: P. Fernandez-Tussy, D. Fernández-Ramos, F. Lopitz-Otsoa, L. Barbier-Torres, I. Zubiete-Franco, V.G. de Juan, J. Bruix, E. Villa, M. Fraga, A.F. Fernández, I. Fabregat, M.J. Perugorria, J.M. Banales, T.C. Delgado, M. Varela-Rey, N. Beraza, S.C. Lu, J.M. Mato, M.L. Martínez-Chantar
Journal: Journal of Hepatology (2016)